Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX1106-02 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MDX1106-02 | DRUG | Single dose |
| Placebo | DRUG | Placebo single dose |
Inclusion Criteria: * Infection with hepatitis C genotype 1 or mixed hepatitis C genotype; * Asymptomatic or nearly asymptomatic from hepatitis C; * Previous therapy with interferon and ribavirin or peginterferon and ribavirin without an SVR or relapsed following an SVR;or Interferon naive subjects...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
MDX1106-02 is an investigational small molecule being developed for the treatment of Hepatitis C, a viral infection of the liver. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
MDX1106-02 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's potential as a treatment for Hepatitis C.
MDX1106-02 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the U.S. Food and Drug Administration or any other regulatory agency. The drug is being studied in a completed Phase 1 trial to assess its safety and tolerability in patients with Hepatitis C.
MDX1106-02 has been studied in one clinical trial, identified as NCT00703469, titled "A Study of MDX-1106 to Treat Patients With Hepatitis C Infection." This Phase 1 trial was completed and enrolled 54 participants in the United States. The study was randomized, double-blind, and placebo-controlled, and it included adults aged 18 years and older.
Yes, MDX1106-02 is the same drug as MDX-1106. The clinical trial NCT00703469 refers to the drug as MDX-1106, and the drug is also known by the name MDX1106-02. Both names refer to the same investigational small molecule being developed for Hepatitis C.